

SUPPLEMENTARY DATA

Supplementary Table 1. Incremental area under the curve (iAUC) of GLP-1 by glucose tolerance status among women and men in the Danish ADDITION-PRO study population.

	NGT	i-IFG	i-IGT	IFG&IGT	SDM	P	P adj.*
Women (n)	389	103	57	54	52		
iAUC30 (nmol/l x min)	288 (75;1275)	266 (60;1245)	278 (45;930)	176 (30;795) ^{a,b,c}	259 (30;990) ^d	0.004	0.004
iAUC120 (nmol/l x min)	1749 (480;6135)	1471 (405;6570) ^a	1570 (465;4755)	1089 (345;3495) ^a	1367 (165;5535)	0.001	0.001
Men (n)	353	165	48	61	104		
iAUC30 (nmol/l x min)	197 (45;975)	183 (45;795)	179 (30;1170)	205 (75;600)	201 (45;975)	0.808	0.756
iAUC120 (nmol/l x min)	1093 (240;4290)	982 (240;3840)	1079 (315;5805)	1015 (255;3255)	911 (135;4215)	0.384	0.752

Data are geometric means (95% CIs). *Adjusted for age and BMI. ^a: P<0.05 vs. NGT; ^b: P<0.05 vs. i-IFG; ^c: P<0.05 vs. i-IGT; ^d: P<0.05 vs. IFG&IGT.

SUPPLEMENTARY DATA

Supplementary Table 2. Sex differences in glucose, insulin, GLP-1 as well as insulin sensitivity and beta cell function in the Danish ADDITION-PRO study population.

	Men	Women	P	P adj.*
N	779	683		
Age (y)	66.5 (6.7)	65.7 (7.4)	0.021	
Height (cm)	176.7 (6.7)	163.5 (6.1)	<0.001	
BMI (kg/m ²)	27.5 (3.9)	26.6 (5.1)	<0.001	
Waist circ. (cm)	100.4 (10.9)	89.8 (13.0)	<0.001	
HbA _{1c} (%)	5.7 (0.4)	5.7 (0.4)	0.972	
HbA _{1c} (mmol/mol)	44.4 (5.3)	44.4 (4.4)	0.972	
Plasma glucose, 0 min (mmol/L)	6.1 (0.8)	5.9 (0.7)	<0.001	<0.001
Plasma glucose, 30 min (mmol/L)	9.4 (1.7)	8.9 (1.8)	<0.001	<0.001
Plasma glucose, 120 min (mmol/L)	7.0 (2.4)	6.6 (2.1)	0.010	0.197
Serum insulin, 0 min (pmol/L)	39.1 (14.0;109.0)	35.3 (13.0;96.0)	0.002	0.150
Serum insulin, 30 min (pmol/L)	218 (76;605)	209 (78;553)	0.214	0.950
Serum insulin, 120 min (pmol/L)	187 (46;843)	188 (60;669)	0.910	0.047
Plasma GLP-1, 0 min (pmol/L)	10.4 (2.0;23.0)	9.3 (1.0;21.0)	0.003	0.017
Plasma GLP-1, 30 min (pmol/L)	25.8 (10.0;76.0)	30.0 (11.0;90.0)	<0.001	<0.001
Plasma GLP-1, 120 min (pmol/L)	17.4 (7.0;36.0)	21.8 (9.0;53.5)	<0.001	<0.001
Plasma GLP-1, tAUC ₀₋₃₀ (pmol/l x min)	565 (195;1320)	618 (225;1530)	0.004	<0.001
Plasma GLP-1, rAUC ₀₋₃₀	1.80 (1.03;5.38)	2.22 (1.1;8)	<0.001	<0.001
Plasma GLP-1, tAUC ₀₋₁₂₀ (pmol/l x min)	2569 (1095;5850)	3039 (1320;7725)	<0.001	<0.001
Plasma GLP-1, rAUC ₀₋₁₂₀	2.06 (1.03;7.31)	2.73 (1.18;11.38)	<0.001	<0.001
Insulinogenic index	53.0 (15.3;206.7)	52.6 (16.5;222.9)	0.914	0.877
Insulin sensitivity index	34.6 (14.2;78.8)	36.2 (16.7;72.1)	0.072	0.988
Disposition index ($\cdot 10^3$)	1.8 (0.4;8.5)	1.9 (0.4;10.0)	0.623	0.884

Data are means (SD) or geometric means (95% CIs). *Adjusted for age and BMI.

SUPPLEMENTARY DATA

Supplementary Figure 1. Mean relative differences (%) with corresponding 95% CIs in early incremental GLP-1 response (iAUC₀₋₃₀, left panel) and full incremental GLP-1 response (iAUC₀₋₁₂₀, right panel) in overweight and obese individuals compared with normal weight individuals in the Danish ADDITION-PRO study population. Gray: unadjusted; black: adjusted for age, sex and glucose tolerance status.

